Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC) [POMEN COX-2 INHIBICIJE V PRVI LINIJI ZDRAVLJENJA RAZSIRJENEGA DROBNOCELICNEGA RAKA PLJUC COX-2]

Trial Profile

Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC) [POMEN COX-2 INHIBICIJE V PRVI LINIJI ZDRAVLJENJA RAZSIRJENEGA DROBNOCELICNEGA RAKA PLJUC COX-2]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs Celecoxib (Primary) ; Antineoplastics
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top